ARGX vs. MCK: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ARGX and MCK, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
MCK stands out with 89.92 billion USD in market value—about 2.52× ARGX’s market cap of 35.72 billion USD.
MCK carries a higher beta at 0.52, indicating it’s more sensitive to market moves, while ARGX remains steadier at 0.17.
ARGX trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while MCK remains a standard domestic listing.
| Symbol | ARGX | MCK |
|---|---|---|
| Company Name | argenx SE | McKesson Corporation |
| Country | NL | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Distribution |
| CEO | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | Mr. Brian S. Tyler Ph.D. |
| Price | 584.95 USD | 718.73 USD |
| Market Cap | 35.72 billion USD | 89.92 billion USD |
| Beta | 0.17 | 0.52 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 18, 2017 | November 10, 1994 |
| ADR | Yes | No |
Performance Comparison
This chart compares the performance of ARGX and MCK over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ARGX and MCK based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- MCK carries a sub-zero price-to-book ratio of -43.39, indicating negative equity. In contrast, ARGX (P/B 7.74) has positive book value.
- ARGX has a negative Price-to-Free Cash Flow ratio of -455.63, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, MCK (P/FCF 16.03) indicates positive free cash flow generation.
| Symbol | ARGX | MCK |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 51.04 | 27.31 |
| Forward PEG Ratio (TTM) | 1.35 | 2.10 |
| Price-to-Sales Ratio (P/S, TTM) | 16.49 | 0.25 |
| Price-to-Book Ratio (P/B, TTM) | 7.74 | -43.39 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -455.63 | 16.03 |
| EV-to-EBITDA (TTM) | 4569.26 | 17.85 |
| EV-to-Sales (TTM) | 15.83 | 0.26 |
| EV-to-Free Cash Flow (TTM) | -437.47 | 16.33 |
Dividend Comparison
ARGX offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while MCK provides a 0.38% dividend yield, giving investors a steady income stream.
| Symbol | ARGX | MCK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.38% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ARGX and MCK, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- MCK’s current ratio of 0.90 indicates its assets may not cover near-term debts, whereas ARGX at 7.29 maintains healthy liquidity.
- MCK posts a quick ratio of 0.53, indicating limited coverage of short-term debts from its most liquid assets—while ARGX at 6.68 enjoys stronger liquidity resilience.
- MCK has negative equity (debt-to-equity ratio -3.56), suggesting asset shortfalls, whereas ARGX at 0.01 preserves healthier equity coverage.
- With negative EBIT (-20.85), ARGX cannot cover its interest payments. MCK, with an interest coverage of 25.45, meets its interest obligations.
| Symbol | ARGX | MCK |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 0.90 |
| Quick Ratio (TTM) | 6.68 | 0.53 |
| Debt-to-Equity Ratio (TTM) | 0.01 | -3.56 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.10 |
| Interest Coverage Ratio (TTM) | -20.85 | 25.45 |